XP0 Stock Chart & Stats
€52.50
-€2.00(-3.54%)
At close: 4:00 PM EDT
€52.50
-€2.00(-3.54%)
Day’s Range― - ―
52-Week Range€29.40 - €62.00
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€3.03B
Enterprise Value€5.09B
Total Cash (Recent Filing)€930.69M
Total Debt (Recent Filing)€6.42M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 11, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.74
Shares Outstanding96,840,430
10 Day Avg. Volume7
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)6.11
Price to Sales (P/S)473.62
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€62.88Price Target Upside19.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-4.1
Revenue Forecast (FY)€1.19M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And LiquidityMinimal leverage and substantial liquidity give Xenon flexibility to fund late-stage trials, prepare a potential U.S. launch, and continue pipeline investment without near-term balance-sheet pressure. The stated runway into 2029 supports sustained execution through multiple development milestones.
Azetukalner Regulatory And Clinical ProgressAn imminent NDA submission represents a meaningful transition from development toward potential commercialization. The sizeable safety dataset and durable open-label seizure outcomes strengthen the package, while regulatory progress could create a clearer path to a recurring product revenue base.
Broadening Late-stage And Pain PipelineMultiple active programs diversify Xenon’s future growth opportunities beyond a single indication or asset. Continued Phase 3 execution in epilepsy and neuropsychiatry, alongside advancing pain candidates, creates several potential clinical catalysts over the next several quarters.
Bears Say
No Meaningful Revenue And Widening LossesXenon remains dependent on development progress rather than an established commercial revenue stream, while losses are expanding materially. This weak earnings foundation increases reliance on liquidity and future financing or successful product launches to support long-term operations.
Heavy And Worsening Cash BurnThe scale and direction of cash outflows show that Xenon is consuming substantial resources to advance its pipeline and prepare commercialization. Even with a long stated runway, persistent burn can erode capital and reduce flexibility if programs or launch plans take longer than expected.
Regulatory Approval Remains UncertainThe company’s near-term commercial strategy depends heavily on a successful regulatory review of azetukalner. A delayed or unfavorable FDA decision would postpone potential revenue, extend cash consumption, and leave Xenon exposed to the costs of continued development without an approved lead product.
Xenon News
XP0 FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was €29.40 and its highest was €62.00 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is €3.03B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Aug 06, 2026. The company reported -€0.989 earnings per share for the quarter, beating the consensus estimate of -€1.016 by €0.028.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.01.
How many shares outstanding does Xenon have?
Xenon has 96,840,430 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -€0.989 in its last earnings report, beating expectations of -€1.016. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in DE:XP0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€62.88 (19.77% Upside)
€62.88 (19.77% Upside)
Blogger Sentiment
Bullish
DE:XP0 Sentiment 63%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €926.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.50%
12-Months-Change
Fundamentals
Return on Equity
-43.98%
Trailing 12-Months
Asset Growth
92.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xenon
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
XP0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple substantive positive developments: an imminent NDA submission supported by strong Phase 3 efficacy and compelling long-term open-label data, a healthy cash position ($1.2B) providing runway into 2029, advancing early-stage pain programs (including confirmed central exposure for Nav1.7) and active commercial build-out with encouraging HCP feedback. Key risks highlighted include the inherent uncertainty of regulatory review, pending readouts for MDD and pain PoC studies, ongoing payer/pricing discussions, common TEAEs that may affect tolerability at higher doses, and potential competition from future Kv7 entrants. On balance, the company's strengths (efficacy, safety dataset, cash runway, advancing pipeline and commercial preparations) outweigh the outstanding uncertainties and execution risks.View all DE:XP0 earnings summariesXP0 Stock 12 Month Forecast
Average Price Target
€62.88
▲(19.77% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Stoke Therapeutics
―
Alto Neuroscience, Inc.
―
Rapport Therapeutics, Inc.
―
Seaport Therapeutics, Inc.
―